Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CureVac (CVAC) Current Deferred Revenue (2019 - 2025)

Historic Current Deferred Revenue for CureVac (CVAC) over the last 7 years, with Q3 2025 value amounting to $693249.7.

  • CureVac's Current Deferred Revenue fell 7351.03% to $693249.7 in Q3 2025 from the same period last year, while for Sep 2025 it was $693249.7, marking a year-over-year decrease of 7351.03%. This contributed to the annual value of $48.0 million for FY2023, which is 3525.56% up from last year.
  • As of Q3 2025, CureVac's Current Deferred Revenue stood at $693249.7, which was down 7351.03% from $196961.0 recorded in Q2 2025.
  • In the past 5 years, CureVac's Current Deferred Revenue registered a high of $789.4 million during Q2 2021, and its lowest value of $99477.3 during Q1 2023.
  • For the 5-year period, CureVac's Current Deferred Revenue averaged around $118.6 million, with its median value being $48.0 million (2023).
  • Per our database at Business Quant, CureVac's Current Deferred Revenue soared by 53568413.06% in 2021 and then tumbled by 9986.64% in 2023.
  • Quarter analysis of 5 years shows CureVac's Current Deferred Revenue stood at $63.8 million in 2021, then plummeted by 44.4% to $35.5 million in 2022, then surged by 35.26% to $48.0 million in 2023, then tumbled by 94.54% to $2.6 million in 2024, then plummeted by 73.51% to $693249.7 in 2025.
  • Its Current Deferred Revenue was $693249.7 in Q3 2025, compared to $196961.0 in Q2 2025 and $2.6 million in Q3 2024.